Advanced search
Publication Cover
Current Medical Research and Opinion Volume 25, 2009 - Issue 12
Submit an article Journal homepage
308
Views
25
CrossRef citations to date
0
Altmetric
Review

Potential neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole

Stefan Albrecht Boehringer Ingelheim GmbHCorrespondence[email protected]
&
Erich Buerger Boehringer Ingelheim Pharma GmbH & Co. KG, Germany
Pages 2977-2987 | Accepted 25 Sep 2009, Published online: 21 Oct 2009

Citations (25)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Ying Wang, Sheng-Gang Sun, Sui-Qiang Zhu, Chun-Feng Liu, Yi-Ming Liu, Qing Di, Hui-Fang Shang, Yan Ren, Wei Xiang & Sheng-Di Chen. (2017) Analysis of pramipexole dose–response relationships in Parkinson’s disease. Drug Design, Development and Therapy 11, pages 83-89.
Read now
Cornelis J Van der Schyf. (2015) Rational drug discovery design approaches for treating Parkinson’s disease. Expert Opinion on Drug Discovery 10:7, pages 713-741.
Read now
Dmitry Petrov, Ignacio Pedros, Maria Luisa de Lemos, Mercè Pallàs, Anna Maria Canudas, Alberto Lazarowski, Carlos Beas-Zarate, Carme Auladell, Jaume Folch & Antoni Camins. (2014) Mavoglurant as a treatment for Parkinson’s disease. Expert Opinion on Investigational Drugs 23:8, pages 1165-1179.
Read now
Philippe Corcia & Paul H Gordon. (2012) Amyotrophic lateral sclerosis and the clinical potential of dexpramipexole. Therapeutics and Clinical Risk Management 8, pages 359-366.
Read now

Articles from other publishers (21)

Robert A. Hauser, Nir Giladi, Werner Poewe, Jonathan Brotchie, Hadas Friedman, Sheila Oren & Pninit Litman. (2022) P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson’s Disease. Advances in Therapy 39:5, pages 1881-1894.
Crossref
Dong-Xin Wang, Ying Yang, Xiao-Song Huang, Jia-Yu Tang, Xi Zhang, Hong-Xing Huang, Bin Zhou, Bo Liu, Hui-Qiong Xiao, Xiao-Hui Li, Ping Yang, Shu-Cheng Zou, Kun Liu, Xiao-Ye Wang & Xiao-Song Li. (2021) Pramipexole attenuates neuronal injury in Parkinson's disease by targeting miR-96 to activate BNIP3-mediated mitophagy. Neurochemistry International 146, pages 104972.
Crossref
Luiz Guilherme Marchesi Mello, Leandro Bortolon Bissoli, Fábio Petersen Saraiva, Raphael de Paula Doyle Maia & Mário Luiz Ribeiro Monteiro. (2020) Retinal Layers and Choroid Measurements in Parkinson's Disease With or Without Pramipexole Treatment. Movement Disorders 35:12, pages 2357-2359.
Crossref
Concepció Marin, Sara Laxe, Cristobal Langdon, Isam Alobid, Joan Berenguer, Mireya Fuentes, Montserrat Bernabeu & Joaquim Mullol. (2019) Olfactory Training Prevents Olfactory Dysfunction Induced by Bulbar Excitotoxic Lesions: Role of Neurogenesis and Dopaminergic Interneurons. Molecular Neurobiology 56:12, pages 8063-8075.
Crossref
Federica Bono, Veronica Mutti, Paola Savoia, Alessandro Barbon, Arianna Bellucci, Cristina Missale & Chiara Fiorentini. (2019) Nicotine prevents alpha-synuclein accumulation in mouse and human iPSC-derived dopaminergic neurons through activation of the dopamine D3- acetylcholine nicotinic receptor heteromer. Neurobiology of Disease 129, pages 1-12.
Crossref
Ho Youn Park, Ju Hee Lee, Soo Young Lee, Dong Soo Yu, Kyung-Do Han, Yong Gyu Park & Young Bok Lee. (2019) Risk for Parkinson’s Disease in Patients with Behçet’s Disease: A Nationwide Population-Based Dynamic Cohort Study in Korea. Journal of Parkinson's Disease 9:3, pages 583-589.
Crossref
Kewal K. JainKewal K. Jain. 2019. The Handbook of Neuroprotection. The Handbook of Neuroprotection 403 463 .
Youssef Sari, Jamie E. Toalston, P.S.S. Rao & Richard L. Bell. (2016) Effects of ceftriaxone on ethanol, nicotine or sucrose intake by alcohol-preferring (P) rats and its association with GLT-1 expression. Neuroscience 326, pages 117-125.
Crossref
Livia S. Moraes, Bruna Z. Rohor, Lorena B. Areal, Evaldo V. Pereira, Alexandre M.C. Santos, Valdir A. Facundo, Adair R.S. Santos, Rita G.W. Pires & Cristina Martins-Silva. (2016) Medicinal plant Combretum leprosum mart ameliorates motor, biochemical and molecular alterations in a Parkinson's disease model induced by MPTP. Journal of Ethnopharmacology 185, pages 68-76.
Crossref
Javier Castro-Hernández, Domingo Afonso-Oramas, Ignacio Cruz-Muros, Josmar Salas-Hernández, Pedro Barroso-Chinea, Rosario Moratalla, Mark J. Millan & Tomás González-Hernández. (2015) Prolonged treatment with pramipexole promotes physical interaction of striatal dopamine D3 autoreceptors with dopamine transporters to reduce dopamine uptake. Neurobiology of Disease 74, pages 325-335.
Crossref
James E. Frampton. (2014) Pramipexole Extended-Release: A Review of Its Use in Patients with Parkinson’s Disease. Drugs 74:18, pages 2175-2190.
Crossref
Rituraj Niranjan. (2013) The Role of Inflammatory and Oxidative Stress Mechanisms in the Pathogenesis of Parkinson’s Disease: Focus on Astrocytes. Molecular Neurobiology 49:1, pages 28-38.
Crossref
Paul Willner, Jørgen Scheel-Krüger & Catherine Belzung. (2013) The neurobiology of depression and antidepressant action. Neuroscience & Biobehavioral Reviews 37:10, pages 2331-2371.
Crossref
Bernardo Dell’Osso, Terence A. Ketter, Laura Cremaschi, Gregorio Spagnolin & A. Carlo Altamura. (2013) Assessing the Roles of Stimulants/Stimulant-like Drugs and Dopamine-agonists in the Treatment of Bipolar Depression. Current Psychiatry Reports 15:8.
Crossref
Wei-li Chang, Martin Weber, Michelle R. Breier, Richard L. Saint Marie, Samantha R. Hines & Neal R. Swerdlow. (2012) Stereochemical and neuroanatomical selectivity of pramipexole effects on sensorimotor gating in rats. Brain Research 1437, pages 69-76.
Crossref
Maria Trinidad Herrero, Javier Pagonabarraga & Gurutz Linazasoro. (2011) Neuroprotective Role of Dopamine Agonists. The Neurologist 17, pages S54-S66.
Crossref
Claire Henchcliffe & W. Lawrence Severt. (2011) Disease Modification in Parkinsonʼs Disease. Drugs & Aging 28:8, pages 605-615.
Crossref
Paul S. Fishman. (2011) Pramipexole and its Extended Release Formulation for Parkinson's Disease. Journal of Central Nervous System Disease 3, pages JCNSD.S5210.
Crossref
Angelo Antonini, Paolo Barone, Roberto Ceravolo, Giovanni Fabbrini, Michele Tinazzi & Giovanni Abbruzzese. (2010) Role of Pramipexole in the Management of Parkinsonʼs Disease. CNS Drugs 24:10, pages 829-841.
Crossref
Chao Li, Yuan Guo, Wenjie Xie, Xingang Li, Joseph Janokovic & Weidong Le. (2010) Neuroprotection of Pramipexole in UPS Impairment Induced Animal Model of Parkinson’s Disease. Neurochemical Research 35:10, pages 1546-1556.
Crossref
Claudine M. Chwieduk & Monique P. Curran. (2010) Pramipexole Extended Release. CNS Drugs 24:4, pages 327-336.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.